Sign Out
The following products are likely to increase the risk of hypoglycemia: Contraindicated combination: Miconazole (systemic route, oromucosal gel).
Combinations which are not recommended: Phenylbutazone (systemic route); Alcohol.
Combinations requiring precautions for use: Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycemia may occur when one of the following drugs is taken: Other antidiabetic agents (insulins, Acarbose, biguanides (e.g. Metformin), Thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), beta-blockers, Fluconazole, angiotensin converting enzyme inhibitors (Captopril, Enalapril), H2-receptor antagonists, monoamine oxidase inhibitors (MAOIs), sulfonamides, Clarithromycin and non-steroidal anti-inflammatory agents.
The following products may cause an increase in blood glucose levels: Combination which is not recommended: Danazol - If the use of this active substance cannot be avoided, warn the patient and emphasize the importance of urine and blood glucose monitoring. It may be necessary to adjust the dose of the antidiabetic agent during and after treatment with Danazol.
Combinations requiring precautions during use: Chlorpromazine (neuroleptic agent); Glucocorticoids (systemic and local route: intra-articular, cutaneous and rectal preparations) and Tetracosactrin; Ritodrine, Salbutamol and Terbutaline (I.V. administration); St. John's Wort (Hypericum perforatum) preparations.
The following products may cause dysglycemia: Combinations requiring precautions during use: Fluoroquinolones - In case of a concomitant use of Gliclazide MR and a fluoroquinolone, the patient should be warned of the risk of dysglycemia, and the importance of blood glucose monitoring should be emphasized.
Combination which must be taken into account: Anticoagulant therapy (e.g. Warfarin) - Sulfonylureas may lead to potentiation of anticoagulation during concurrent treatment. Adjustment of the anticoagulant therapy may be necessary.
